ABG Sundal Collier acted as Sole Global Coordinator and Sole Bookrunner in Nanexa’s SEK 17m directed share issue to Novo Nordisk

On Wednesday 21 December 2022, Nanexa announced the successful completion of a directed share issue of 10,000,000 shares at a price of SEK 1.72 per share to Novo Nordisk A/S, raising proceeds of SEK 17.2m. The subscription price is equivalent to a premium of 33 percent versus the closing price for Nanexa’s shares on Nasdaq First North Growth Market 20 December 2022 and a premium of 10 percent versus the volume weighted average price of the last twenty trading days for Nanexa’s shares on Nasdaq First North Growth Market preceding 20 December 2022.
Novo Nordisk’s investment in Nanexa is made in connection with the signing of a Material Transfer and Feasibility Study Agreement worth approximately SEK 46.1m for the evaluation of Nanexa’s drug delivery system PharmaShell® with Novo Nordisk products. In total, Nanexa will thus receive SEK 63.3m.
This marks the second transaction ABG Sundal Collier completes with Nanexa, having acted as Sole Global Coordinator and Sole Bookrunner in Nanexa’s 2021 rights issue, raising gross proceeds of approximately SEK 127m.